Corbus Pharmaceuticals Holdings (CRBP) Other Non-Current Liabilities (2016 - 2023)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Other Non-Current Liabilities of $44000.0 for Q4 2023, up 98.15% year-over-year from $22205.0 in Q4 2022, and down 0.92% quarter-over-quarter from $44410.0 in Q3 2023.
Corbus Pharmaceuticals Holdings (CRBP) Other Non-Current Liabilities (2016 - 2023) Analysis & Trends
Corbus Pharmaceuticals Holdings' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $44000.0 for Q4 2023.
- In Q4 2023, Other Non-Current Liabilities rose 98.15% year-over-year to $44000.0; the TTM figure through Dec 2023 stood at $44000.0 (up 98.15% YoY), while the FY2023 annual figure was $44000.0, up 98.15% from the prior year.
- Other Non-Current Liabilities for Q4 2023 stood at $44000.0, down from $44410.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $2.5 million in Q1 2023, with the low at $797.0 in Q4 2020.
- The 4-year median for Other Non-Current Liabilities is $22205.0 (2021), against an average of $328741.7.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 97.23% in 2022, then jumped 11258.73% in 2023.
- Corbus Pharmaceuticals Holdings' Other Non-Current Liabilities stood at $797.0 in 2020, then soared by 2686.07% to $22205.0 in 2021, then changed by 0.0% to $22205.0 in 2022, then jumped by 98.15% to $44000.0 in 2023.
- Business Quant data shows CRBP's Other Non-Current Liabilities at $44000.0 in Q4 2023, $44410.0 in Q3 2023, and $22205.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 44,410.00 |
| Jun 30, 2023 | 22,205.00 |
| Mar 31, 2023 | 2.52 Mn |
| Dec 31, 2022 | 22,205.00 |
| Sep 30, 2022 | 22,205.00 |
| Jun 30, 2022 | 22,205.00 |
| Mar 31, 2022 | 22,205.00 |
| Dec 31, 2021 | 22,205.00 |
| Sep 30, 2021 | 127,000.00 |
| Jun 30, 2021 | 599,000.00 |
| Mar 31, 2021 | 803,000.00 |
| Dec 31, 2020 | 797.00 |
| Dec 31, 2017 | 375.00 |
| Sep 30, 2017 | 1,482.00 |
| Jun 30, 2017 | 2,559.00 |
| Mar 31, 2017 | 3,609.00 |
| Dec 31, 2016 | 4,632.00 |
| Sep 30, 2016 | 15,503.00 |
| Jun 30, 2016 | 15,190.00 |